Rubén Niesvizky

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text

Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

Donna M. Weber, Christine Chen, Rubén Niesvizky et al. · New England Journal of Medicine · 2007 · 1.2K citations · Full text

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Sundar Jagannath, Bart Barlogie, James R. Berenson et al. · British Journal of Haematology · 2004 · 739 citations · Full text

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 483 citations · Full text

Hematological Malignancy, Magnetismm-3 Trial Results, Medicine +13

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Meletios Α. Dimopoulos, Hartmut Goldschmidt, Rubén Niesvizky et al. · The Lancet Oncology · 2017 · 401 citations

Hematological Malignancy, Oncology, Pathology +4